top of page
REVERT
A MULTICENTER, RANDOMIZED, PHASE II TRIAL EVALUATING THE EFFICACY OF ERIBULIN MONOTHERAPY AND ERIBULIN PLUS ENDOCRINE THERAPY IN LOCALLY-RECURRENT OR METASTATIC BREAST CANCER PATIENTS AFTER PROGRESSION ON ENDOCRINE THERAPY (REVERT).
CLINICAL TRIAL DETAILS
THE PRIMARY ENDPOINT IS THE OVERALL RESPONSE RATE IN THE ARM CORRESPONDING TO THE PATIENTS TREATED WITH ERIBULIN IN COMBINATION WITH AROMATASE INHIBITOR THERAPY BASED ON LOCAL INVESTIGATOR’S ASSESSMENT ACCORDING TO RECIST V.1.1. REVERT IS A SIMON’S TWO-STAGE ADMISSIBLE DESIGN CLINICAL TRIAL, 60 PATIENTS WILL BE INCLUDED, 22 IN STAGE I AND 38 IN STAGE II. PATIENTS WILL RECEIVE ERIBULIN INJECTIONS INTRAVENOUSLY ON DAYS 1 AND 8 OF EVERY 21-DAY CYCLE, ALONE OR IN COMBINATION WITH ENDOCRINE THERAPY (AROMATASE INHIBITOR).
COUNTRY
STATUS
TUMOR TYPE
PHASE
N
SITES
BREAST
9
60
II
Spain
Closing
TRIAL OVERVIEW
PRESS RELEASE
-----
SCIENTIFIC IMPACT
BLOG ARTICLES RELATED
Interviewing Dr. Ana López on MEDSIR REVERT TRIAL (advanced metastatic breast cancer)
REVERT Study Poster Presentation at SABCS 2019
TRIAL SITES
Hospital Universitario Miguel Servet (Spain)
Complejo Hospitalario de Jaén (Spain)
Hospital Universitario Ramón y Cajal (Spain)
Hospital Universitario La Paz (Spain)
Hospital Universitario de León (Spain)
Hospital Son Llatzer (Spain)
Hospital Universitari Dexeus (Spain)
Hospital Universitario Dr. Peset (Spain)
Institut Català d'Oncologia Girona (ICO) (Spain)
Dr. Cortes and Dr. Llombart PHERain interview
Beyond Chemotherapy
Dr. Vanes Quiroga
Dr. Sofia Braga
Dr. Silvi Antolín
Dr. Escrivá de Romaní
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley
bottom of page